|
1) Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate. 2004; 61: 332-53
|
|
|
|
2) Schnee JM, Hsueh WA. Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc Res. 2000; 46: 264-8
|
|
|
|
|
|
3) Uemura H, Ishiguro H, Nakaigawa N, et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther. 2003; 2: 1139-47
|
|
|
|
|
|
4) Culig Z, Comuzzi B, Steiner H, et al. Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol. 2004; 92: 265-71
|
|
|
|
|
|
5) Uemura H, Nakaigawa N, Ishiguro H, et al. Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. Curr Cancer Drug Targets. 2005; 5: 307-23
|
|
|
|
|
|
6) Yasunari K, Maeda K, Nakamura M, et al. Left ventricular hypertrophy and angiotensin II receptor blocking agents. Curr Med Chem Cardiovasc Hematol Agents. 2005; 3: 61-7
|
|
|
|
|
|
7) Castro-Chaves P, Leite-Moreira AF. Renin-angiotensin system and its role in cardiovascular physiopathology and therapy. Rev Port Cardiol. 2004; 23 Suppl 2: II61-77
|
|
|
|
|
|
8) Miyazaki M, Takai S. Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci. 2006; 100: 391-7
|
|
|
|
|
9) Ino K, Shibata K, Kajiyama H, et al. Manipulating the angiotensin system--new approaches to the treatment of solid tumours. Expert Opin Biol Ther. 2006; 6: 243-55
|
|
|
|
|
|
10) Dinh DT, Frauman AG, Somers GR, et al. Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. J Pathol. 2002; 196: 213-9
|
|
|
|
|
|
11) Nassis L, Frauman AG, Ohishi M, et al. Localization of angiotensin-converting enzyme in the human prostate: pathological expression in benign prostatic hyperplasia. J Pathol. 2001; 195: 571-9
|
|
|
|
|
|
12) O'Mahony OA, Barker S, Puddefoot JR, et al. Synthesis and secretion of angiotensin II by the prostate gland in vitro. Endocrinology. 2005; 146: 392-8
|
|
|
|
|
|
13) Ishiguro H, Ishiguro Y, Kubota Y, et al. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate. 2007; 67: 924-32
|
|
|
|
|
|
14) Penela P, Ribas C, Mayor F, Jr. Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cell Signal. 2003; 15: 973-81
|
|
|
|
|
|
15) Li S, Huang S, Peng SB. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol. 2005; 27: 1329-39
|
|
|
|
|
|
16) Vessella RL, Corey E. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res. 2006; 12: 6285-90s
|
|
|
|
|
|
17) Lee SO, Lou W, Johnson CS, et al. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate. 2004; 60: 178-86
|
|
|
|
|
|
18) Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate. 2000; 42: 150-60
|
|
|
|
|
|
19) Uemura H, Ishiguro H, Nagashima Y, et al. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol Cancer Ther. 2005; 4: 1699-709
|
|
|
|
|
|
20) Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer？ Lancet. 1998; 352: 179- 84
|
|
|
|
|
|
21) Uemura H, Hasumi H, Kawahara T, et al. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol. 2005; 10: 405-10
|
|
|
|
|
|
22) Tuck ML. Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system. Curr Hypertens Rep. 2005; 7: 240-3
|
|
|
|
|
|
23) Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes. 2005; 54: 3442-52
|
|
|
|
|
|
24) Feinstein DL, Spagnolo A, Akar C, et al. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key？ Biochem Pharmacol. 2005; 70: 177-88
|
|
|
|
|
|
25) Ito T, Ikeda U. Inflammatory cytokines and cardiovascular disease. Curr Drug Targets Inflamm Allergy. 2003; 2: 257-65
|
|
|
|
|